SJS Investment Consulting
INMB icon

SJS Investment Consulting’s INmune Bio INMB Stock Holding History

SJS Investment Consulting’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-41
Closed -$67 – 3292
2026
Q2 		$67 Buy
41
+32
+356% +$44 ﹤0.01% 2681
2026
Q1 		$11 Buy
+9
New +$13 ﹤0.01% 2420

Other funds holding INMB

Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Westside Investment Management
Westside Investment Management Santa Monica, California $785M AUM 29.89% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
AXQ Capital
AXQ Capital Jersey City, New Jersey $764M AUM 4.44% 1-Year Est. Return

SJS Investment Consulting's INMB Position: Q3 2026 in Review

SJS Investment Consulting sold out of INmune Bio (INMB) in Q3 2026, closing a stake of 41 shares — an estimated $67 sold.

SJS Investment Consulting first reported a position in INMB in Q1 2026 and held it in 2 quarters. The position peaked at $67 in Q2 2026. 37 funds tracked by Wall St. Rank hold INMB as of Q3 2026.

  • SJS Investment Consulting reported no remaining INmune Bio position as of Q3 2026 after selling out during the quarter.
  • SJS Investment Consulting sold 41 INmune Bio shares in Q3 2026, an estimated $67.
  • SJS Investment Consulting first reported a position in INmune Bio in Q1 2026 and held it in 2 quarters.
  • SJS Investment Consulting's INmune Bio position peaked at $67 in Q2 2026.
  • 37 funds tracked by Wall St. Rank held INmune Bio as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.